亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國OncoMed  
OncoMed制藥是一個臨床階段的公司發現并開發新型療法，針對癌癥干細胞，細胞認為是能夠驅動腫瘤生長，復發和轉移。癌癥干細胞研究的領導者，該公司已建立了癌癥干細胞的蛋白質抗體庫的實體腫瘤，如胰腺癌，乳腺癌，腸癌和肺癌的治療。 OncoMed已推進到診所指，OMP-21M18-59R5，OMP的，和OMP-18R5，該目標的關鍵癌癥干細胞的信號包括Notch和Wnt信號通路的三防癌干細胞的單克隆抗體。此外，OncoMed的管道包括了一些新的臨床前候選產品，針對多個驗證癌癥干細胞的途徑。 OncoMed與拜耳醫藥保健制藥和葛蘭素史克公司已形成戰略聯盟。私人持有，OncoMed的投資者包括：The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.


OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti- cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed's investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.